Immuneering (IMRX) Accumulated Expenses: 2020-2024
Historic Accumulated Expenses for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $4.6 million.
- Immuneering's Accumulated Expenses rose 39.22% to $4.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $4.6 million, marking a year-over-year increase of 39.22%. This contributed to the annual value of $5.2 million for FY2023, which is 14.95% up from last year.
- Immuneering's Accumulated Expenses amounted to $4.6 million in Q3 2024, which was up 22.24% from $3.8 million recorded in Q2 2024.
- Immuneering's 5-year Accumulated Expenses high stood at $5.2 million for Q4 2023, and its period low was $698,992 during Q4 2020.
- For the 3-year period, Immuneering's Accumulated Expenses averaged around $3.4 million, with its median value being $3.3 million (2023).
- Per our database at Business Quant, Immuneering's Accumulated Expenses soared by 467.31% in 2021 and then slumped by 32.91% in 2022.
- Quarterly analysis of 5 years shows Immuneering's Accumulated Expenses stood at $698,992 in 2020, then soared by 467.31% to $4.0 million in 2021, then grew by 13.51% to $4.5 million in 2022, then climbed by 14.95% to $5.2 million in 2023, then skyrocketed by 39.22% to $4.6 million in 2024.
- Its Accumulated Expenses was $4.6 million in Q3 2024, compared to $3.8 million in Q2 2024 and $2.6 million in Q1 2024.